Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01379
|
|||||
| Drug Name |
Mequitazine
|
|||||
| Synonyms |
Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Allergic rhinitis [ICD11: CA08.0] | Approved | [1] | |||
| Therapeutic Class |
Antihistamines
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H22N2S
|
|||||
| Canonical SMILES |
C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
|
|||||
| InChI |
InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
|
|||||
| InChIKey |
HOKDBMAJZXIPGC-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 29216-28-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 322.5 | Topological Polar Surface Area | 31.8 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
4.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
453325
, 583144
, 7366094
, 7848387
, 8141047
, 8152552
, 10320045
, 10517343
, 11406959
, 14850608
, 16617285
, 26665232
, 29223177
, 46505779
, 48416221
, 50006661
, 53787706
, 56320321
, 57322124
, 57962172
, 78247115
, 81093314
, 85209426
, 87244027
, 92714662
, 103267575
, 103815311
, 104305332
, 104972177
, 117404379
, 124799813
, 124894252
, 125347181
, 126623962
, 126655271
, 126669303
, 128089981
, 131309176
, 134338335
, 134997033
, 137267684
, 140724147
, 142143428
, 144207197
, 160964405
, 163121882
, 164761785
, 164814342
, 170005238
, 170465794
|
|||||
| ChEBI ID |
CHEBI:31821
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (Y463242LY2) | |||||
| 2 | Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.